Several other equities analysts also recently weighed in on the stock. Morgan Stanley raised shares of Zoetis from an equal weight rating to an overweight rating and set a $80.00 price target on the stock in a report on Wednesday, November 29th. Jefferies Group reaffirmed a buy rating on shares of Zoetis in a report on Friday, November 10th. Zacks Investment Research downgraded shares of Zoetis from a buy rating to a hold rating in a report on Wednesday, November 1st. BidaskClub raised shares of Zoetis from a sell rating to a hold rating in a report on Friday, October 13th. Finally, Cantor Fitzgerald set a $80.00 price target on shares of Zoetis and gave the stock a buy rating in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. Zoetis presently has an average rating of Buy and an average target price of $71.94.
Zoetis (ZTS) traded up $0.80 on Monday, hitting $75.39. 1,915,600 shares of the company were exchanged, compared to its average volume of 2,368,844. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The stock has a market capitalization of $36,740.00, a P/E ratio of 39.68, a price-to-earnings-growth ratio of 1.90 and a beta of 1.06. Zoetis has a one year low of $52.00 and a one year high of $75.69.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. Zoetis’s payout ratio is 22.11%.
A number of hedge funds have recently bought and sold shares of ZTS. Nisa Investment Advisors LLC lifted its position in Zoetis by 0.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 253,456 shares of the company’s stock worth $18,259,000 after buying an additional 2,180 shares during the period. Daiwa SB Investments Ltd. raised its position in shares of Zoetis by 92.0% during the 4th quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock valued at $1,308,000 after acquiring an additional 8,696 shares during the last quarter. Milestone Resources Group Ltd bought a new stake in shares of Zoetis during the 4th quarter valued at $40,294,000. Chesley Taft & Associates LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $1,027,000. Finally, Hutchens Investment Management Inc raised its position in shares of Zoetis by 15.0% during the 4th quarter. Hutchens Investment Management Inc now owns 13,798 shares of the company’s stock valued at $994,000 after acquiring an additional 1,798 shares during the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.